Literature DB >> 18405971

Iron overload in myelodysplastic syndromes: a Canadian consensus guideline.

Richard A Wells, Brian Leber, Rena Buckstein, Jeffrey H Lipton, Wanda Hasegawa, Kuljit Grewal, Karen Yee, Harold J Olney, Loree Larratt, Linda Vickars, Alan Tinmouth.   

Abstract

In December 2005, 11 Canadian hematologists met to develop an evidence-based clinical practice guideline that would address the diagnosis, monitoring, management, and rationale for the treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). This Expert Panel consisted of hematologists from across Canada, each with an active practice in a major population centre or a rural area. Based on an extensive literature search and years of clinical experience, their mandate was to address common clinical practice questions, particularly why treat, whom to treat, when to initiate treatment, and how to treat iron overload in patients with MDS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18405971     DOI: 10.1016/j.leukres.2008.02.021

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  15 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Prognostic significance of serum ferritin level at diagnosis in myelodysplastic syndrome.

Authors:  Shohei Kikuchi; Masayoshi Kobune; Satoshi Iyama; Tsutomu Sato; Kazuyuki Murase; Yutaka Kawano; Kohichi Takada; Kaoru Ono; Tsuyoshi Hayashi; Koji Miyanishi; Yasushi Sato; Rishu Takimoto; Junji Kato
Journal:  Int J Hematol       Date:  2012-03-11       Impact factor: 2.490

Review 3.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

4.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

Review 5.  Guidelines on haemovigilance of post-transfusional iron overload.

Authors:  Angel Remacha; Cristina Sanz; Enric Contreras; Cristina Díaz De Heredia; Joan Ramón Grifols; Montserrat Lozano; Guillermo Martín Nuñez; Ramón Salinas; Mercedes Corral; Ana Villegas
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

Review 6.  An update on iron chelation therapy.

Authors:  Erika Poggiali; Elena Cassinerio; Laura Zanaboni; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-06-27       Impact factor: 3.443

7.  Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement.

Authors:  Bor-Sheng Ko; Cheng-Shyong Chang; Ming-Chih Chang; Tsai Yun Chen; Tzeon-Jye Chiou; Chang-Fang Chiu; Wen-Li Huang; Woei-Yau Kao; Yii-Jenq Lan; Shen-Fung Lin; Tran-Der Tan; Jih-Luh Tang; Cheng-Hwai Tzeng; Po-Nan Wang; Su-Pen Yet; Hwei-Fang Tien
Journal:  Int J Hematol       Date:  2014-06-13       Impact factor: 2.490

8.  Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.

Authors:  Norbert Gattermann; Carlo Finelli; Matteo Della Porta; Pierre Fenaux; Michael Stadler; Agnes Guerci-Bresler; Mathias Schmid; Kerry Taylor; Dominique Vassilieff; Dany Habr; Andrea Marcellari; Bernard Roubert; Christian Rose
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

9.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

10.  Iron overload in patients undergoing hematopoietic stem cell transplantation.

Authors:  Vinod Pullarkat
Journal:  Adv Hematol       Date:  2010-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.